Published in Front Immunol on March 17, 2014
The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer. Front Immunol (2015) 1.08
Advantages and applications of CAR-expressing natural killer cells. Front Pharmacol (2015) 1.03
Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective. Front Immunol (2014) 0.95
Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease. Mucosal Immunol (2015) 0.91
Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies. Front Immunol (2015) 0.88
TIM-3/Gal-9 interaction induces IFNγ-dependent IDO1 expression in acute myeloid leukemia blast cells. J Hematol Oncol (2015) 0.87
Selection and expansion of natural killer cells for NK cell-based immunotherapy. Cancer Immunol Immunother (2016) 0.84
Advances in clinical NK cell studies: Donor selection, manufacturing and quality control. Oncoimmunology (2015) 0.84
Immunotherapeutic applications of NK cells. Pharmaceuticals (Basel) (2015) 0.84
Going back to class I: MHC and immunotherapies for childhood cancer. Pediatr Blood Cancer (2014) 0.80
A multifaceted approach targeting NK cells for better treatment of cancer: focus on hematological malignancies. Blood Res (2015) 0.76
NK receptors: tools for a polyvalent cell family. Front Immunol (2014) 0.76
Engineering Natural Killer Cells for Cancer Immunotherapy. Mol Ther (2017) 0.76
Matrine increases NKG2D ligand ULBP2 in K562 cells via inhibiting JAK/STAT3 pathway: a potential mechanism underlying the immunotherapy of matrine in leukemia. Am J Transl Res (2015) 0.75
Cellular immunotherapy as a beacon of hope for hematological malignancies. Blood Res (2015) 0.75
CD56 in the Immune System: More Than a Marker for Cytotoxicity? Front Immunol (2017) 0.75
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science (2002) 12.75
Functions of natural killer cells. Nat Immunol (2008) 9.88
Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature (1986) 9.73
Human NK cell education by inhibitory receptors for MHC class I. Immunity (2006) 6.73
Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science (1995) 5.41
Human diversity in killer cell inhibitory receptor genes. Immunity (1997) 4.82
HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med (2012) 4.52
Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood (2010) 4.46
KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol (2001) 4.24
Hematopoietic colony-forming cells derived from human embryonic stem cells. Proc Natl Acad Sci U S A (2001) 4.07
Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood (2003) 3.88
Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity (1997) 3.84
Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains. Immunity (1995) 3.72
Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood (2005) 3.65
The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med (1995) 3.43
HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci U S A (1998) 3.35
Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor. Immunity (1996) 3.33
Natural killer cell developmental pathways: a question of balance. Annu Rev Immunol (2006) 3.31
Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood (2008) 3.18
The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant (2006) 2.93
Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood (2009) 2.88
Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy (2009) 2.71
Molecular cloning of NKB1. A natural killer cell receptor for HLA-B allotypes. J Immunol (1995) 2.63
Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood (1996) 2.62
Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med (1989) 2.61
NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules. J Exp Med (1994) 2.59
Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer. Immunity (1995) 2.37
Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res (2009) 2.37
Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood (2007) 2.36
Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity (2007) 2.20
NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: the rheostat model. J Immunol (2009) 2.12
Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One (2012) 2.09
Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood (2002) 2.03
A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy (2010) 1.99
MHC class I-deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I-sufficient environment. J Exp Med (2010) 1.95
Human killer cell activatory receptors for MHC class I molecules are included in a multimeric complex expressed by natural killer cells. J Immunol (1997) 1.92
Continuous engagement of a self-specific activation receptor induces NK cell tolerance. J Exp Med (2008) 1.86
Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. Cytotherapy (2010) 1.85
Tolerance of NK cells encountering their viral ligand during development. J Exp Med (2008) 1.82
KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia (2009) 1.80
Allelic polymorphism synergizes with variable gene content to individualize human KIR genotype. J Immunol (2002) 1.79
Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood (2006) 1.79
Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells. Blood (2009) 1.73
Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity. J Immunol (2005) 1.67
A single amino acid in the p58 killer cell inhibitory receptor controls the ability of natural killer cells to discriminate between the two groups of HLA-C allotypes. J Immunol (1997) 1.63
NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions. Blood (2011) 1.62
Natural killer cell tolerance licensing and other mechanisms. Adv Immunol (2009) 1.60
Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. Blood (2005) 1.58
Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood (2009) 1.57
A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells. Hum Immunol (2001) 1.57
Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. Blood (2009) 1.51
Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15. Blood (1998) 1.51
Phosphotyrosines in the killer cell inhibitory receptor motif of NKB1 are required for negative signaling and for association with protein tyrosine phosphatase 1C. J Exp Med (1996) 1.50
A novel phosphotyrosine motif with a critical amino acid at position -2 for the SH2 domain-mediated activation of the tyrosine phosphatase SHP-1. J Biol Chem (1997) 1.50
High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy. PLoS One (2010) 1.46
Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant (2006) 1.42
Tyrosine phosphorylation of a human killer inhibitory receptor recruits protein tyrosine phosphatase 1C. J Exp Med (1996) 1.42
Enhancement of human cord blood CD34+ cell-derived NK cell cytotoxicity by dendritic cells. J Immunol (2001) 1.41
Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One (2011) 1.39
Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. Haematologica (2011) 1.37
T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation. Br J Haematol (2003) 1.34
A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia (2005) 1.33
The generation of human natural killer cells from CD34+/DR- primitive progenitors in long-term bone marrow culture. Blood (1992) 1.32
Ex vivo expansion of natural killer cells for clinical applications. Cytotherapy (2004) 1.31
Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation. Blood (2010) 1.30
Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells. Biol Blood Marrow Transplant (2008) 1.30
Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children. Klin Padiatr (2005) 1.26
Identification of a cellular ligand for the natural cytotoxicity receptor NKp44. Blood (2013) 1.25
Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation (2006) 1.24
Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol (2005) 1.23
Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity. Blood (2013) 1.22
Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood (2004) 1.21
Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation. Clin Exp Immunol (2007) 1.20
TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica (2005) 1.19
Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy (2013) 1.17
Signaling through human killer cell activating receptors triggers tyrosine phosphorylation of an associated protein complex. Eur J Immunol (1998) 1.15
NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation. Blood (2010) 1.14
NK-cell education is shaped by donor HLA genotype after unrelated allogeneic hematopoietic stem cell transplantation. Blood (2010) 1.08
Use of natural killer cells in hematopoetic stem cell transplantation. Bone Marrow Transplant (2005) 1.08
Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients. Cytotherapy (2010) 1.07
Polymorphism and domain variability of human killer cell inhibitory receptors. Immunol Rev (1997) 1.05
Ex vivo expansion of natural killer cells with high cytotoxicity by K562 cells modified to co-express major histocompatibility complex class I chain-related protein A, 4-1BB ligand, and interleukin-15. Tissue Antigens (2010) 1.04
Inhibitory killer Ig-like receptor genes and human leukocyte antigen class I ligands in haematopoietic stem cell transplantation. Curr Opin Immunol (2004) 1.04
A novel myeloid-like NK cell progenitor in human umbilical cord blood. Blood (2002) 1.02
Expansion and activation of natural killer cells for cancer immunotherapy. Korean J Lab Med (2009) 1.02
Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. Cytotherapy (2003) 1.01
Natural killer cells: a review of manufacturing and clinical utility. Transfusion (2012) 1.00
Donor killer immunoglobulin-like receptor (KIR) genotype-patient cognate KIR ligand combination and antithymocyte globulin preadministration are critical factors in outcome of HLA-C-KIR ligand-mismatched T cell-replete unrelated bone marrow transplantation. Biol Blood Marrow Transplant (2008) 0.99
Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells. Blood (2003) 0.98
NK cell tolerance of self-specific activating receptor KIR2DS1 in individuals with cognate HLA-C2 ligand. J Immunol (2013) 0.97
Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol. Front Oncol (2013) 0.97
NK cells differentiated from bone marrow, cord blood and peripheral blood stem cells exhibit similar phenotype and functions. Eur J Immunol (1998) 0.96
Genesis of human oncolytic natural killer cells from primitive CD34+CD33- bone marrow progenitors. J Immunol (1993) 0.94
Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies. Front Immunol (2015) 0.88